JP2022190161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022190161A5 JP2022190161A5 JP2022178239A JP2022178239A JP2022190161A5 JP 2022190161 A5 JP2022190161 A5 JP 2022190161A5 JP 2022178239 A JP2022178239 A JP 2022178239A JP 2022178239 A JP2022178239 A JP 2022178239A JP 2022190161 A5 JP2022190161 A5 JP 2022190161A5
- Authority
- JP
- Japan
- Prior art keywords
- hms5552
- solid dispersion
- pharmaceutical
- polymer carrier
- metformin hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HMUMWSORCUWQJO-QAPCUYQASA-N (2s)-2-[3-(2-chlorophenoxy)-5-oxo-2h-pyrrol-1-yl]-n-[1-[(2r)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide Chemical compound C=1C(=O)N([C@@H](CC(C)C)C(=O)NC2=NN(C[C@@H](O)CO)C=C2)CC=1OC1=CC=CC=C1Cl HMUMWSORCUWQJO-QAPCUYQASA-N 0.000 claims 85
- 239000007962 solid dispersion Substances 0.000 claims 77
- 229920000642 polymer Polymers 0.000 claims 59
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 47
- 229940124828 glucokinase activator Drugs 0.000 claims 45
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims 44
- 229960004329 metformin hydrochloride Drugs 0.000 claims 43
- 229940000425 combination drug Drugs 0.000 claims 42
- 229940123208 Biguanide Drugs 0.000 claims 36
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 36
- 239000003472 antidiabetic agent Substances 0.000 claims 36
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 34
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 30
- 125000000129 anionic group Chemical group 0.000 claims 30
- 239000013066 combination product Substances 0.000 claims 24
- 229940127555 combination product Drugs 0.000 claims 24
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 24
- 239000003826 tablet Substances 0.000 claims 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims 14
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 13
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 12
- 229960001681 croscarmellose sodium Drugs 0.000 claims 12
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 8
- 239000008103 glucose Substances 0.000 claims 8
- 201000001421 hyperglycemia Diseases 0.000 claims 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000013078 crystal Substances 0.000 claims 7
- 239000011777 magnesium Substances 0.000 claims 7
- 229910052749 magnesium Inorganic materials 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 6
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 235000019359 magnesium stearate Nutrition 0.000 claims 6
- 108091000080 Phosphotransferase Proteins 0.000 claims 5
- 239000012190 activator Substances 0.000 claims 5
- 229910002055 micronized silica Inorganic materials 0.000 claims 5
- 102000020233 phosphotransferase Human genes 0.000 claims 5
- 239000000741 silica gel Substances 0.000 claims 5
- 208000002249 Diabetes Complications Diseases 0.000 claims 4
- 206010012655 Diabetic complications Diseases 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 4
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 206010033307 Overweight Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000000945 filler Substances 0.000 claims 4
- 230000002641 glycemic effect Effects 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 229960003105 metformin Drugs 0.000 claims 4
- -1 methacrylate ester Chemical class 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 230000000291 postprandial effect Effects 0.000 claims 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 229960000913 crospovidone Drugs 0.000 claims 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 229960004111 buformin Drugs 0.000 claims 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 239000003086 colorant Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000007941 film coated tablet Substances 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 150000003840 hydrochlorides Chemical class 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 229960003243 phenformin Drugs 0.000 claims 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 150000003890 succinate salts Chemical class 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001464 adherent effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 235000019691 monocalcium phosphate Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940071138 stearyl fumarate Drugs 0.000 claims 1
- 239000008030 superplasticizer Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810556685.6 | 2018-05-31 | ||
| CN201810556685 | 2018-05-31 | ||
| JP2020566564A JP7479696B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| PCT/CN2019/088861 WO2019228362A1 (zh) | 2018-05-31 | 2019-05-28 | 含葡萄糖激酶激活剂和双胍类降糖药物的药物组合、组合物和复方制剂及其制备方法和用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566564A Division JP7479696B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022190161A JP2022190161A (ja) | 2022-12-22 |
| JP2022190161A5 true JP2022190161A5 (https=) | 2023-05-29 |
Family
ID=68697184
Family Applications (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566675A Active JP7265276B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｓｇｌｔ－２阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566564A Active JP7479696B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566565A Pending JP2021525722A (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびα−グルコシダーゼ阻害剤を含む医薬品の組合せ、組成物、製剤、ならびにその調製方法および使用 |
| JP2020566718A Active JP7565589B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｄｐｐ－ｉｖ阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566720A Pending JP2021525741A (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｐｐａｒ受容体活性化剤を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566710A Pending JP2021525739A (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｋ−ａｔｐチャネル遮断薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178239A Pending JP2022190161A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178201A Pending JP2022190159A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびα－グルコシダーゼ阻害剤を含む医薬品の組合せ、組成物、製剤、ならびにその調製方法および使用 |
| JP2022178269A Pending JP2022190162A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｋ－ａｔｐチャネル遮断薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178296A Pending JP2022190165A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｓｇｌｔ－２阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178345A Pending JP2022190168A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｐｐａｒ受容体活性化剤を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178385A Pending JP2022190170A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｄｐｐ－ｉｖ阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566675A Active JP7265276B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｓｇｌｔ－２阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566564A Active JP7479696B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566565A Pending JP2021525722A (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびα−グルコシダーゼ阻害剤を含む医薬品の組合せ、組成物、製剤、ならびにその調製方法および使用 |
| JP2020566718A Active JP7565589B2 (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｄｐｐ－ｉｖ阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566720A Pending JP2021525741A (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｐｐａｒ受容体活性化剤を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2020566710A Pending JP2021525739A (ja) | 2018-05-31 | 2019-05-28 | グルコキナーゼ活性化剤およびｋ−ａｔｐチャネル遮断薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178201A Pending JP2022190159A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびα－グルコシダーゼ阻害剤を含む医薬品の組合せ、組成物、製剤、ならびにその調製方法および使用 |
| JP2022178269A Pending JP2022190162A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｋ－ａｔｐチャネル遮断薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178296A Pending JP2022190165A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｓｇｌｔ－２阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178345A Pending JP2022190168A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｐｐａｒ受容体活性化剤を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2022178385A Pending JP2022190170A (ja) | 2018-05-31 | 2022-11-07 | グルコキナーゼ活性化剤およびｄｐｐ－ｉｖ阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US12318366B2 (https=) |
| EP (6) | EP3804714B1 (https=) |
| JP (12) | JP7265276B2 (https=) |
| KR (7) | KR20210016437A (https=) |
| CN (12) | CN110548148B (https=) |
| AU (6) | AU2019278015B2 (https=) |
| BR (6) | BR112020024203A2 (https=) |
| CA (4) | CA3101832A1 (https=) |
| DK (3) | DK3804714T3 (https=) |
| ES (3) | ES3017250T3 (https=) |
| FI (3) | FI3804714T3 (https=) |
| HR (3) | HRP20250258T1 (https=) |
| HU (3) | HUE070297T2 (https=) |
| IL (6) | IL279037B2 (https=) |
| LT (3) | LT3804716T (https=) |
| MX (6) | MX2020012965A (https=) |
| PL (3) | PL3804716T3 (https=) |
| PT (3) | PT3804716T (https=) |
| RS (3) | RS66566B1 (https=) |
| RU (1) | RU2770775C1 (https=) |
| SG (6) | SG11202011883RA (https=) |
| SI (3) | SI3804714T1 (https=) |
| SM (3) | SMT202500104T1 (https=) |
| TW (6) | TWI778268B (https=) |
| WO (6) | WO2019228364A1 (https=) |
| ZA (6) | ZA202007688B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019278015B2 (en) * | 2018-05-31 | 2024-10-03 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| WO2021151251A1 (en) * | 2020-01-31 | 2021-08-05 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| AU2020443475A1 (en) * | 2020-04-22 | 2022-11-17 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor |
| US11813274B2 (en) | 2020-04-22 | 2023-11-14 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor |
| CA3185831A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| AU2020451966A1 (en) * | 2020-06-04 | 2023-01-19 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CN111759838B (zh) * | 2020-07-02 | 2022-01-25 | 深圳微芯生物科技股份有限公司 | 西格列他的可药用盐药物组合物及其应用 |
| CN112206216B (zh) * | 2020-10-15 | 2023-03-17 | 江西华士药业有限公司 | 一种缓释达格列净的制备方法 |
| CN116234545A (zh) * | 2020-11-19 | 2023-06-06 | 北京睿创康泰医药研究院有限公司 | 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途 |
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| CN113527265B9 (zh) * | 2021-02-02 | 2022-07-19 | 湖南南新制药股份有限公司 | 一种氘代吡咯烷酮衍生物、药物组合物及其用途 |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| CN113750100B (zh) * | 2021-08-31 | 2022-12-30 | 海南中济医药科技有限公司 | 一种含有多扎格列艾汀与西格列汀的药物组合物及其制备方法 |
| AR127064A1 (es) | 2021-09-15 | 2023-12-13 | Hua Medicine Shanghai Ltd | Prodroga de derivados de pirrolidona como activador de glucoquinasa |
| TR2022010735A1 (tr) * | 2022-06-29 | 2024-01-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Empagli̇flozi̇n i̇çeren bi̇r tablet |
| CN115598234B (zh) * | 2022-09-06 | 2025-05-30 | 株洲千金药业股份有限公司 | 一种检测利格列汀对映异构体的方法及应用 |
| AR132113A1 (es) * | 2023-03-13 | 2025-05-28 | Hua Medicine Shanghai Ltd | Forma sólida de derivados de pirrolidona como activador de glucoquinasa |
| CN121586585A (zh) * | 2023-04-11 | 2026-02-27 | 肽智科技私人有限公司 | 用于上调肌细胞中肌营养相关蛋白水平的化合物及其应用方法 |
| IL325046A (en) * | 2023-06-06 | 2026-02-01 | Hua Medicine Shanghai Ltd | Activates glucokinase for cognitive disorders and neurodegenerative diseases |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| CN117815193A (zh) * | 2023-11-30 | 2024-04-05 | 重庆康刻尔制药股份有限公司 | 一种盐酸二甲双胍恩格列净控释片及其制备方法 |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| TW202541799A (zh) * | 2023-12-14 | 2025-11-01 | 美商華領醫藥美國有限公司 | 包含葡萄糖激酶激活劑之醫藥調配物及其用途 |
| CN120361228B (zh) * | 2025-04-08 | 2025-11-21 | 复旦大学附属妇产科医院 | 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| ITFI20010230A1 (it) | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
| CA2543498A1 (en) | 2003-10-27 | 2005-05-06 | Innodia Inc. | Use of hydroxylated amino acids for treating diabetes |
| CA2540225C (en) | 2003-10-31 | 2012-03-06 | Takeda Pharmaceutical Company Limited | Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester |
| US7687502B2 (en) | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| AU2006250354A1 (en) | 2005-05-23 | 2006-11-30 | Japan Tobacco Inc. | Pyrazole compound and therapeutic agent for diabetes comprising the same |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US7910747B2 (en) * | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
| AU2007316613B2 (en) | 2006-11-09 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
| EP2573087A1 (en) * | 2007-09-21 | 2013-03-27 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| US7741327B2 (en) * | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| KR20110018366A (ko) | 2008-05-16 | 2011-02-23 | 다케다 샌디에고, 인코포레이티드 | 글루코키나아제 활성제 |
| TWI492943B (zh) | 2008-12-05 | 2015-07-21 | 大塚製藥股份有限公司 | 喹啉酮化合物及藥學組成物（二） |
| CN102369205B (zh) | 2009-01-30 | 2014-10-29 | 武田药品工业株式会社 | 稠环化合物和其用途 |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| EP2604604A1 (en) * | 2009-03-11 | 2013-06-19 | Pfizer Inc | Benzofuranyl derivatives used as glucokinase inhibitors |
| WO2010107610A1 (en) | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| EP2498759B1 (en) * | 2009-11-13 | 2018-08-01 | AstraZeneca AB | Immediate release tablet formulations |
| WO2011060255A1 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
| NZ603614A (en) | 2010-05-26 | 2014-10-31 | Transtech Pharma Llc | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| CN102558167A (zh) | 2010-12-29 | 2012-07-11 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的噻唑烷二酮衍生物 |
| ES2448398T3 (es) | 2011-06-03 | 2014-03-13 | Ratiopharm Gmbh | Composición farmacéutica que comprende dapagliflozina y ciclodextrina |
| BR112014028622A2 (pt) * | 2012-05-17 | 2017-06-27 | Transtech Pharma Llc | composições de ativador de glucoquinase para o tratamento de diabetes |
| DK2921489T3 (en) * | 2012-11-13 | 2017-10-16 | Nissan Chemical Ind Ltd | 2-pyridone-RELATED |
| TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN104208034B (zh) * | 2013-12-11 | 2017-11-07 | 重庆康刻尔制药有限公司 | 一种格列美脲药物组合物片剂、制备方法及其应用 |
| CN103655539B (zh) | 2013-12-13 | 2019-09-13 | 重庆医药工业研究院有限责任公司 | 一种卡格列净的口服固体制剂及其制备方法 |
| CN104840960A (zh) * | 2014-02-14 | 2015-08-19 | 广东东阳光药业有限公司 | 抗糖尿病的药物组合物及其制备方法 |
| TW201625605A (zh) * | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| WO2015176267A1 (en) * | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US20180369325A1 (en) | 2015-11-19 | 2018-12-27 | Garvan Institute Of Medical Research | Compounds and methods for treating metabolic disorders |
| US20190070120A1 (en) | 2016-03-10 | 2019-03-07 | Aurobindo Pharma Ltd. | Pharmaceutical Composition Comprising Canagliflozin, Process of Preparation and Use Thereof |
| CN106474480A (zh) | 2016-11-15 | 2017-03-08 | 深圳奥萨医疗有限公司 | 含有葡萄糖激酶激动剂和b族维生素的药物组合物及其用途 |
| EP3556354B1 (en) * | 2016-12-15 | 2025-05-21 | Hua Medicine (Shanghai) Ltd. | Oral preparation of glucokinase activator and preparation method therefor |
| AU2019278015B2 (en) * | 2018-05-31 | 2024-10-03 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof |
-
2019
- 2019-05-28 AU AU2019278015A patent/AU2019278015B2/en active Active
- 2019-05-28 PT PT198116915T patent/PT3804716T/pt unknown
- 2019-05-28 BR BR112020024203-9A patent/BR112020024203A2/pt not_active Application Discontinuation
- 2019-05-28 AU AU2019278018A patent/AU2019278018B2/en not_active Ceased
- 2019-05-28 ES ES19811691T patent/ES3017250T3/es active Active
- 2019-05-28 MX MX2020012965A patent/MX2020012965A/es unknown
- 2019-05-28 CN CN201910453725.9A patent/CN110548148B/zh active Active
- 2019-05-28 RU RU2020143045A patent/RU2770775C1/ru active
- 2019-05-28 WO PCT/CN2019/088863 patent/WO2019228364A1/zh not_active Ceased
- 2019-05-28 EP EP19810783.1A patent/EP3804714B1/en active Active
- 2019-05-28 CN CN201910453723.XA patent/CN110548026B/zh active Active
- 2019-05-28 IL IL279037A patent/IL279037B2/en unknown
- 2019-05-28 SM SM20250104T patent/SMT202500104T1/it unknown
- 2019-05-28 MX MX2020012970A patent/MX2020012970A/es unknown
- 2019-05-28 SG SG11202011883RA patent/SG11202011883RA/en unknown
- 2019-05-28 MX MX2020012966A patent/MX2020012966A/es unknown
- 2019-05-28 US US17/059,148 patent/US12318366B2/en active Active
- 2019-05-28 HU HUE19811377A patent/HUE070297T2/hu unknown
- 2019-05-28 PL PL19811691.5T patent/PL3804716T3/pl unknown
- 2019-05-28 CA CA3101832A patent/CA3101832A1/en active Pending
- 2019-05-28 LT LTEPPCT/CN2019/088863T patent/LT3804716T/lt unknown
- 2019-05-28 US US17/058,936 patent/US12064416B2/en active Active
- 2019-05-28 JP JP2020566675A patent/JP7265276B2/ja active Active
- 2019-05-28 BR BR112020024348-5A patent/BR112020024348A2/pt unknown
- 2019-05-28 MX MX2020012972A patent/MX2020012972A/es unknown
- 2019-05-28 JP JP2020566564A patent/JP7479696B2/ja active Active
- 2019-05-28 FI FIEP19810783.1T patent/FI3804714T3/fi active
- 2019-05-28 SI SI201930909T patent/SI3804714T1/sl unknown
- 2019-05-28 EP EP19811691.5A patent/EP3804716B1/en active Active
- 2019-05-28 CN CN202111599185.9A patent/CN114028574A/zh active Pending
- 2019-05-28 US US17/058,883 patent/US11992477B2/en active Active
- 2019-05-28 KR KR1020207037957A patent/KR20210016437A/ko not_active Ceased
- 2019-05-28 SG SG11202011886TA patent/SG11202011886TA/en unknown
- 2019-05-28 AU AU2019278017A patent/AU2019278017A1/en not_active Abandoned
- 2019-05-28 CN CN202111599191.4A patent/CN114159570B/zh active Active
- 2019-05-28 PT PT198113771T patent/PT3804715T/pt unknown
- 2019-05-28 CN CN202111599339.4A patent/CN114209694A/zh active Pending
- 2019-05-28 PT PT198107831T patent/PT3804714T/pt unknown
- 2019-05-28 WO PCT/CN2019/088864 patent/WO2019228365A1/zh not_active Ceased
- 2019-05-28 KR KR1020207037950A patent/KR102695130B1/ko active Active
- 2019-05-28 EP EP19810210.5A patent/EP3804712A4/en not_active Withdrawn
- 2019-05-28 EP EP19810441.6A patent/EP3804713A4/en not_active Withdrawn
- 2019-05-28 HR HRP20250258TT patent/HRP20250258T1/hr unknown
- 2019-05-28 AU AU2019278013A patent/AU2019278013B2/en active Active
- 2019-05-28 DK DK19810783.1T patent/DK3804714T3/da active
- 2019-05-28 CN CN202111601625.XA patent/CN114010793B/zh active Active
- 2019-05-28 WO PCT/CN2019/088865 patent/WO2019228366A1/zh not_active Ceased
- 2019-05-28 ES ES19810783T patent/ES3016532T3/es active Active
- 2019-05-28 DK DK19811377.1T patent/DK3804715T3/da active
- 2019-05-28 HU HUE19810783A patent/HUE070296T2/hu unknown
- 2019-05-28 JP JP2020566565A patent/JP2021525722A/ja active Pending
- 2019-05-28 SM SM20250112T patent/SMT202500112T1/it unknown
- 2019-05-28 HR HRP20250268TT patent/HRP20250268T1/hr unknown
- 2019-05-28 SM SM20250107T patent/SMT202500107T1/it unknown
- 2019-05-28 CN CN201910453079.6A patent/CN110548147B/zh active Active
- 2019-05-28 SG SG11202011888VA patent/SG11202011888VA/en unknown
- 2019-05-28 JP JP2020566718A patent/JP7565589B2/ja active Active
- 2019-05-28 EP EP19812252.5A patent/EP3811939A4/en not_active Withdrawn
- 2019-05-28 CN CN201910453726.3A patent/CN110548149B/zh active Active
- 2019-05-28 BR BR112020024269-1A patent/BR112020024269A2/pt not_active Application Discontinuation
- 2019-05-28 SG SG11202011884QA patent/SG11202011884QA/en unknown
- 2019-05-28 US US17/058,903 patent/US11963947B2/en active Active
- 2019-05-28 IL IL279036A patent/IL279036B2/en unknown
- 2019-05-28 WO PCT/CN2019/088861 patent/WO2019228362A1/zh not_active Ceased
- 2019-05-28 ES ES19811377T patent/ES3015131T3/es active Active
- 2019-05-28 FI FIEP19811377.1T patent/FI3804715T3/fi active
- 2019-05-28 RS RS20250232A patent/RS66566B1/sr unknown
- 2019-05-28 SG SG11202011881PA patent/SG11202011881PA/en unknown
- 2019-05-28 CN CN201910453724.4A patent/CN110548027B/zh active Active
- 2019-05-28 CA CA3101826A patent/CA3101826A1/en active Pending
- 2019-05-28 US US17/058,863 patent/US11666556B2/en active Active
- 2019-05-28 US US17/058,929 patent/US20210214312A1/en not_active Abandoned
- 2019-05-28 KR KR1020247017725A patent/KR20240091095A/ko not_active Abandoned
- 2019-05-28 BR BR112020024125-3A patent/BR112020024125A2/pt unknown
- 2019-05-28 CN CN202111601610.3A patent/CN114246950A/zh active Pending
- 2019-05-28 MX MX2020012967A patent/MX2020012967A/es unknown
- 2019-05-28 WO PCT/CN2019/088866 patent/WO2019228367A1/zh not_active Ceased
- 2019-05-28 KR KR1020207038034A patent/KR102695132B1/ko active Active
- 2019-05-28 CA CA3101825A patent/CA3101825A1/en active Pending
- 2019-05-28 JP JP2020566720A patent/JP2021525741A/ja active Pending
- 2019-05-28 AU AU2019278014A patent/AU2019278014B2/en not_active Ceased
- 2019-05-28 RS RS20250231A patent/RS66565B1/sr unknown
- 2019-05-28 MX MX2020012969A patent/MX2020012969A/es unknown
- 2019-05-28 SG SG11202011893UA patent/SG11202011893UA/en unknown
- 2019-05-28 LT LTEPPCT/CN2019/088864T patent/LT3804715T/lt unknown
- 2019-05-28 EP EP19811377.1A patent/EP3804715B1/en active Active
- 2019-05-28 CN CN201910453076.2A patent/CN110548146B/zh active Active
- 2019-05-28 IL IL279035A patent/IL279035B2/en unknown
- 2019-05-28 LT LTEPPCT/CN2019/088861T patent/LT3804714T/lt unknown
- 2019-05-28 BR BR112020024271-3A patent/BR112020024271A2/pt not_active Application Discontinuation
- 2019-05-28 RS RS20250230A patent/RS66564B1/sr unknown
- 2019-05-28 PL PL19811377.1T patent/PL3804715T3/pl unknown
- 2019-05-28 HU HUE19811691A patent/HUE070298T2/hu unknown
- 2019-05-28 PL PL19810783.1T patent/PL3804714T3/pl unknown
- 2019-05-28 IL IL279039A patent/IL279039B2/en unknown
- 2019-05-28 JP JP2020566710A patent/JP2021525739A/ja active Pending
- 2019-05-28 DK DK19811691.5T patent/DK3804716T3/da active
- 2019-05-28 KR KR1020207037631A patent/KR102695126B1/ko active Active
- 2019-05-28 CA CA3101822A patent/CA3101822C/en active Active
- 2019-05-28 KR KR1020207037560A patent/KR102695135B1/ko active Active
- 2019-05-28 SI SI201930906T patent/SI3804715T1/sl unknown
- 2019-05-28 CN CN202111601620.7A patent/CN114259491A/zh active Pending
- 2019-05-28 WO PCT/CN2019/088862 patent/WO2019228363A1/zh not_active Ceased
- 2019-05-28 HR HRP20250257TT patent/HRP20250257T1/hr unknown
- 2019-05-28 KR KR1020207037642A patent/KR102703153B1/ko active Active
- 2019-05-28 FI FIEP19811691.5T patent/FI3804716T3/fi active
- 2019-05-28 SI SI201930907T patent/SI3804716T1/sl unknown
- 2019-05-28 AU AU2019278016A patent/AU2019278016B2/en active Active
- 2019-05-28 BR BR112020024107-5A patent/BR112020024107A2/pt unknown
- 2019-05-31 TW TW108118940A patent/TWI778268B/zh active
- 2019-05-31 TW TW108118939A patent/TWI706947B/zh active
- 2019-05-31 TW TW108118901A patent/TWI794503B/zh active
- 2019-05-31 TW TW108118896A patent/TWI761681B/zh active
- 2019-05-31 TW TW108118937A patent/TWI765157B/zh not_active IP Right Cessation
- 2019-05-31 TW TW108118936A patent/TWI764000B/zh active
-
2020
- 2020-11-27 IL IL279034A patent/IL279034A/en unknown
- 2020-11-27 IL IL279040A patent/IL279040A/en unknown
- 2020-12-09 ZA ZA2020/07688A patent/ZA202007688B/en unknown
- 2020-12-09 ZA ZA2020/07678A patent/ZA202007678B/en unknown
- 2020-12-09 ZA ZA2020/07679A patent/ZA202007679B/en unknown
- 2020-12-09 ZA ZA2020/07681A patent/ZA202007681B/en unknown
- 2020-12-09 ZA ZA2020/07687A patent/ZA202007687B/en unknown
- 2020-12-09 ZA ZA2020/07671A patent/ZA202007671B/en unknown
-
2022
- 2022-11-07 JP JP2022178239A patent/JP2022190161A/ja active Pending
- 2022-11-07 JP JP2022178201A patent/JP2022190159A/ja active Pending
- 2022-11-07 JP JP2022178269A patent/JP2022190162A/ja active Pending
- 2022-11-07 JP JP2022178296A patent/JP2022190165A/ja active Pending
- 2022-11-07 JP JP2022178345A patent/JP2022190168A/ja active Pending
- 2022-11-07 JP JP2022178385A patent/JP2022190170A/ja active Pending
-
2023
- 2023-05-03 US US18/311,846 patent/US20230346748A1/en not_active Abandoned
-
2024
- 2024-03-19 US US18/610,100 patent/US20240299357A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022190161A5 (https=) | ||
| JP2022190165A5 (https=) | ||
| JP2022190170A5 (https=) | ||
| FI3804714T3 (fi) | Farmaseuttinen yhdistelmä, koostumus ja yhdistelmä-valmiste, joka käsittää glukokinaasin aktivaattorin ja veren glukoosipitoisuutta alentavan biguanidilääkkeen sekä niiden valmistusmenetelmä ja käyttö | |
| US7985422B2 (en) | Dosage form | |
| US8007824B2 (en) | Galenic formulations of organic compounds | |
| JP5798269B2 (ja) | 薬物高含量錠剤 | |
| EP4051246B1 (en) | Bilayer tablet formulations comprising dapagliflozin and metformin | |
| TWI606848B (zh) | 包含格米列汀與美氟明的組合藥物及其製備方法 | |
| WO2005065639A2 (en) | Novel pharmaceutical compositions | |
| US20230172863A1 (en) | Modified-release dosage forms of ruxolitinib | |
| US20150250734A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| RU2020143179A (ru) | Фармацевтическая комбинация, композиция и состав, содержащие активатор глюкокиназы и ингибитор альфа-глюкозидазы, способы приготовления и их применение | |
| RU2020143156A (ru) | Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и бигуанидное гипогликемическое лекарственное средство, а также способ их приготовления и их применение | |
| WO2024128996A1 (en) | Monolayer tablet composition of empagliflozin and metformin hydrochloride | |
| WO2025106043A1 (en) | A bilayer tablet composition comprising dapagliflozin and metformin | |
| EP4556001A1 (en) | A bilayer tablet composition comprising dapagliflozin and metformin | |
| TR2023007477A2 (tr) | Linagliptin & metformin içeren monolitik tablet bileşimi. | |
| TR2022013349A2 (tr) | Li̇nagli̇pti̇n i̇hti̇va eden farmasöti̇k kompozi̇syonlar | |
| EA052094B1 (ru) | Фармацевтическая композиция, содержащая ингибитор sglt2 | |
| WO2020240594A1 (en) | A pharmaceutical composition for diabetes mellitus |